What is FloShield?
FloShield operates at the intersection of medical device engineering and surgical efficiency, specializing in advanced laparoscopic vision solutions. The company's core value proposition centers on its proprietary Vortex Barrier Technology, which is integrated into products such as FloShield Air and FloShield Plus. This technology addresses a critical pain point in minimally invasive surgery by protecting laparoscope lenses from condensation, debris, and smoke. By enabling intra-operative lens cleaning without the need to remove the scope, FloShield significantly optimizes surgical workflow, reduces procedure duration, and lowers overall operational costs for healthcare providers. Its universal compatibility with various laparoscopic systems positions the company as an essential partner for surgical teams seeking to enhance precision and patient outcomes.
How much funding has FloShield raised?
FloShield has raised a total of $15.5M across 3 funding rounds:
Private Equity
$1.4M
Private Equity
$2M
Series C
$12.1M
Private Equity (2008): $1.4M with participation from Canaan Partners, Radius Ventures, and Charter Life Sciences
Private Equity (2010): $2M led by Canaan Partners, Radius Ventures, and Charter Life Sciences
Series C (2015): $12.1M supported by Canaan Partners and Radius Ventures
Key Investors in FloShield
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
Radius Ventures
Radius Ventures was a venture capital firm focused on building innovative companies in the health and life sciences sectors, recognized for its disciplined, domain-driven investment approach.
Charter Life Sciences
Charter Life Sciences is a life sciences venture capital firm that focuses on providing initial venture capital to companies developing innovative products for significant unmet medical needs.
What's next for FloShield?
With the successful completion of this major enterprise-level funding, FloShield is well-positioned to accelerate its commercial expansion and deepen its penetration into global surgical markets. The strategic focus will likely shift toward scaling manufacturing capabilities to meet rising demand and potentially expanding the product portfolio to address additional challenges in the operating room. As the company transitions into its next phase of maturity, the emphasis will remain on maintaining its technological edge through rigorous R&D and strategic partnerships. By leveraging its established reputation for reliability and innovation, FloShield is poised to further disrupt traditional surgical practices, ultimately driving long-term value for stakeholders and improving the standard of care in laparoscopic procedures.
See full FloShield company page
